Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Anderson

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Journal of Thrombosis and Haemostasis : JTH|January 29, 2023
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolismLucia Caiano, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Journal of Occupational and Environmental Medicine|January 24, 2014
The predictive validity of the HERO Scorecard in determining future health care cost and risk trendsRon Z Goetzel, Rachel Mosher Henke, Richele Benevent, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
Discovery of indazoles as inhibitors of Tpl2 kinaseYonghan Hu, Derek Cole, Rajiah Aldrin Denny, et al.
BMJ (Clinical Research Ed.)|June 10, 2021
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trialMichael J Kovacs, Philip S Wells, David R Anderson, et al.
Thrombosis Research|October 6, 2023
Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: Data from the REVERSE cohort studyYan Xu, Faizan Khan, Michael J Kovacs, et al.
Journal of Medicinal Chemistry|October 27, 2012
Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assayChristoph W Zapf, Brian S Gerstenberger, Li Xing, et al.
BMJ (Clinical Research Ed.)|March 19, 2017
Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management studyMarc A Rodger, Gregoire Le Gal, David R Anderson, et al.
The American Journal of Medicine|April 13, 2017
Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort StudySusan R Kahn, Arash Akaberi, John T Granton, et al.
Journal of Thrombosis and Haemostasis : JTH|March 16, 2021
Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort studyDavid Aziz, Leslie Skeith, Marc A Rodger, et al.
The Annals of Pharmacotherapy|March 17, 2005
Influence of warfarin on symptoms of fatigue: findings of a randomized trialMichael J Kovacs, Clive Kearon, Jim A Julian, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Journal of Thrombosis and Haemostasis : JTH|January 29, 2023
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolismLucia Caiano, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Journal of Occupational and Environmental Medicine|January 24, 2014
The predictive validity of the HERO Scorecard in determining future health care cost and risk trendsRon Z Goetzel, Rachel Mosher Henke, Richele Benevent, et al.
Bioorganic & Medicinal Chemistry Letters|July 12, 2011
Discovery of indazoles as inhibitors of Tpl2 kinaseYonghan Hu, Derek Cole, Rajiah Aldrin Denny, et al.
BMJ (Clinical Research Ed.)|June 10, 2021
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trialMichael J Kovacs, Philip S Wells, David R Anderson, et al.
Thrombosis Research|October 6, 2023
Serial D-dimers after anticoagulant cessation in unprovoked venous thromboembolism: Data from the REVERSE cohort studyYan Xu, Faizan Khan, Michael J Kovacs, et al.
Journal of Medicinal Chemistry|October 27, 2012
Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assayChristoph W Zapf, Brian S Gerstenberger, Li Xing, et al.
BMJ (Clinical Research Ed.)|March 19, 2017
Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management studyMarc A Rodger, Gregoire Le Gal, David R Anderson, et al.
The American Journal of Medicine|April 13, 2017
Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort StudySusan R Kahn, Arash Akaberi, John T Granton, et al.
Journal of Thrombosis and Haemostasis : JTH|March 16, 2021
Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort studyDavid Aziz, Leslie Skeith, Marc A Rodger, et al.
The Annals of Pharmacotherapy|March 17, 2005
Influence of warfarin on symptoms of fatigue: findings of a randomized trialMichael J Kovacs, Clive Kearon, Jim A Julian, et al.
Pageof 15